Lab-Grown Blood - Could Hospitals Eventually Manufacture Blood For Transfusions?

1 hour ago
4 min read

Human Blood. The one thing that cannot be made or ordered is a main staple needed in hospitals. Blood donations are essential for our health systems, essential for patients undergoing surgeries, cancer patients, accident victims, people with blood disorders, and countless other emergencies within our hospitals. However donated blood has an obvious limitation. It depends on people who are willing and able to donate. You may be thinking “What if hospitals could make their own blood they need?” This idea is not so far out of reach as some may think. Researchers have successfully grown human red blood cells in labs, and these cells have been transfused into human volunteers as part of clinical research. The technology is still very experimental, very expensive, and nowhere near ready to replace a typical blood donation. However, it does raise the thought, could hospitals produce blood on demand?

The goal is not to make blood for the entire blood supply from scratch. Instead, scientists are focusing on the red blood cells, which carry oxygen from the lungs to the rest of the body. Researchers can use blood-forming stem cells taken from adult donors and encourage them to develop into red blood cells under carefully controlled laboratory conditions. The cells receive nutrients and biological signals that guide their development. However the challenge is scale. A blood donation contains an enormous number of red blood cells. Growing enough cells for a transfusion requires specialized equipment, large-scale cell cultures, and strict quality control. The UK Government’s Engineering Biology Aspirations report identifies scalable bioreactors and automated manufacturing as important steps toward producing laboratory-grown red blood cells in clinically useful quantities.

One of the biggest breakthroughs has already happened. NHS Blood and Transplant and its research partners conducted the RESTORE clinical trial, in which laboratory-grown red blood cells were transfused into human volunteers. According to NHS Blood and Transplant, the manufactured cells were grown from stem cells obtained from blood donors. Volunteers received small amounts of either laboratory-grown or standard donated red blood cells so researchers could compare how the cells behaved in the bloodstream. Researchers are particularly interested in how long these manufactured cells survive. Normally, donated blood contains red blood cells of different ages. Laboratory-grown cells can potentially be produced at a more consistent stage of development. The RESTORE trial is specifically investigating whether manufactured red blood cells survive longer in circulation than standard donated cells. This could eventually benefit patients who require regular transfusions, including some with sickle cell disease or thalassemia. However, a successful clinical trial does not mean laboratory-grown blood is ready to replace donated blood.

The biggest potential advantage is supply. Hospitals sometimes face blood shortages, while patients with rare blood types can be especially difficult to match with compatible donors. A manufactured source of red blood cells could eventually provide a more predictable supply. Laboratory production might also make it possible to create cells with particular characteristics. Researchers are exploring whether carefully selected or genetically modified cell lines could produce red blood cells compatible with larger patient groups. For people who need repeated transfusions, the benefits could be significant. If manufactured cells last longer in the bloodstream, patients might eventually need fewer transfusions. The technology could also improve access during emergencies. The UK Government’s 2025 report describes a future in which lab-grown blood could help rare blood groups, shortages, and challenges with traditional blood supplies.

The biggest obstacles are cost, scale, regulation, and safety. The human body produces red blood cells very efficiently. Replicating that process in a laboratory is difficult. Scientists must grow huge numbers of cells, mature them, remove unwanted material, and show the final product is safe and can work like red blood cells do naturally in the body. Then comes the manufacturing challenges. Producing enough cells for a research study is very different from producing enough for thousands upon thousands of patients. Large-scale production of the red blood cells would require specialized and trained personnel and a reliable quality-control system. The UK Government’s engineering biology report identifies scale-up, clinical validation, investment, regulated standards, and a development plan of major challenges that must be addressed before widespread use becomes anywhere close to realistic. Cost is another major question you may now be thinking about. Donated blood is already a resource that is well kept in hospitals. A laboratory-grown alternative would have to become affordable for most people to come close to justifying the additional manufacturing costs.

A more realistic future could involve specialized centers to manufacture the lab-grown red blood cells on a larger scale. Hospitals could then receive them through their medical supply chains and connections. If production becomes cheaper, smaller facilities might eventually be able to produce these red blood cells. However, that would require major advances in regulation approvals and major advances in cell production and manufacturing. . It is also important to remember that blood is more than red blood cells. Whole blood contains platelets, white blood cells, plasma, white blood cells, and other contents. Successfully made blood cells do not immediately or automatically solve the problem of producing every part needed for a transfusion.

We are still long away from switching a machine on and producing a blood bag on demand. But science has moved beyond theory. Lab-grown red blood cells have already reached human clinical trials, and researchers are working on the difficult next steps of lowering costs, producing larger quantities, proving the safety and effectiveness, and developing a reliable system of manufacturing. If those challenges are overcome, lab-grown blood could give doctors more lifesaving options, especially when on low supply or the patient has a difficult blood type to match. For now, donated blood is not able to be given to patients. But someday, alongside the typical blood banks, hospitals may have another source of lifesaving treatment.